Company: RNGE
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001641172-25-001343
Chunk: 198

Company: RANGE IMPACT, INC.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 1A
Chunk 198
---
 and the assumptions made to calculate the fair value of option awards included in this table are described in Footnote
6 of the financial statements and the accompanying notes for the years ended December 31, 2024 and December 31, 2023 appearing elsewhere
in this Annual Report.

(2)
Based on the fair value of an option to purchase 1,000,000 shares of common stock with an exercise price of $0.212 per share, granted
in December 2023.

(3)
Ms. Missal was appointed to the CFO role on April 25, 2024. Previously she served as Controller. The value of the option award is based on the fair value of an option
to purchase 250,000 shares of common stock with an exercise price of $0.38 per share, granted in April 2024.

(4)
Mr. McKilligan moved to serve as CFO of Graphium Biosciences effective April 25, 2024 and remained with that entity until it was spun
off in September 2024.

(5)
Dr. Zipp moved to serve as Chief Science Officer of Graphium Biosciences effective April 25, 2024 and remained with that entity until
it was spun off in September 2024.

35

Outstanding
Equity Awards at December 31, 2024

    Option
    Awards

    Number
    of securities underlying unexercised option  
    Option
    Exercise  
    Option Expiration

    Grant
    Date 
    Exercisable  
    Unexercisable  
    Price
    ($)  
    Date
  
    Michael Cavanaugh (1) 
    5/8/2019 
     500,000  
     -  
     0.35  
    5/8/2029

    6/27/2019 
     250,000  
     -  
     0.30  
    6/27/2029

    12/10/2021 
     350,000  
     -  
     0.277  
    12/10/2031

    11/30/2022 
     750,000  
        
     0.18  
    11/30/2032

    12/21/2023 
     1,000,000